Physician calls for "radical new approach" to MS after positive Alemtuzumab Phase II 5-Year review
This article was originally published in Scrip
Executive Summary
A lead investigator in the Phase 2 CAMMS223 trial of Genzyme's alemtuzumab (CamPath-H1) has called for " a radical new approach" to treatment of multiple sclerosis on the basis of 5-year follow up data presented on 14 October at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) International Conference in Goteborg, Sweden. Dr Alasdair Coles from the Department of Clinical Neurosciences, University of Cambridge hopes that MS physicians will look at the data from the study and move quickly to aggressive treatments such as alemtuzumab before overt and severe disability emerges, rather than adopting the "wait-and-see" approach with MS patients.